RIPK3 and colitis: Given the pronounced response that we had seen in ADAM17ex/ex and ADAM17ex/ex/RIPK3−/− mice in the acute colitis model, we speculated that the employed treatment regimen of 1.5% DSS might have overpowered any protection that lack of RIPK3 might have conferred to the ADAM17ex/ex/RIPK3−/− mice.